Cargando…

Plasma Osteopontin Level in Chronic Liver Disease and Hepatocellular Carcinoma

BACKGROUND: Osteopontin (OPN) is a secreted glycoprotein and is frequently associated with various tumors. OBJECTIVES: We sought to investigate the clinical usefulness of the level of plasma OPN, compared to α-fetoprotein (AFP), as a biomarker for hepatocellular carcinoma (HCC) and to evaluate its d...

Descripción completa

Detalles Bibliográficos
Autores principales: Fouad, Shawky Abdelhamid, Mohamed, Nagwa Abdel Ghaffar, Fawzy, Mary Wadie, Moustafa, Doaa Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612688/
https://www.ncbi.nlm.nih.gov/pubmed/26500684
http://dx.doi.org/10.5812/hepatmon.30753
_version_ 1782396202756603904
author Fouad, Shawky Abdelhamid
Mohamed, Nagwa Abdel Ghaffar
Fawzy, Mary Wadie
Moustafa, Doaa Ali
author_facet Fouad, Shawky Abdelhamid
Mohamed, Nagwa Abdel Ghaffar
Fawzy, Mary Wadie
Moustafa, Doaa Ali
author_sort Fouad, Shawky Abdelhamid
collection PubMed
description BACKGROUND: Osteopontin (OPN) is a secreted glycoprotein and is frequently associated with various tumors. OBJECTIVES: We sought to investigate the clinical usefulness of the level of plasma OPN, compared to α-fetoprotein (AFP), as a biomarker for hepatocellular carcinoma (HCC) and to evaluate its diagnostic value in nonalcoholic fatty liver disease (NAFLD) and its relationship with clinical and laboratory features of HCC and NAFLD. PATIENTS AND METHODS: The study was performed on 120 subjects classified into 5 groups: Group I included 25 chronic non-cirrhotic hepatitis C virus (HCV)-infected patients; Group II encompassed 25 patients with chronic HCV infection with liver cirrhosis; Group III comprised 25 patients with chronic HCV with liver cirrhosis and HCC; Group IV was comprised of 25 patients with NAFLD; and Group V consisted of 20 healthy age- and sex-matched controls. All the participants were subjected to history taking and clinical and abdominal ultrasonographic examinations as well as the following laboratory investigations: liver function tests, complete blood count, blood sugar, hepatitis B surface antigen, hepatitis C virus antibodies, HCV-RNA by qualitative polymerase chain reaction (for Groups I, II, and III) and serum AFP and plasma OPN levels. RESULTS: There were statistically significant differences in plasma OPN levels between the HCC group (401 ± 72 ng/mL) and the other groups, between the cirrhotic group (258.3 ± 35 ng/mL) and the non-cirrhotic group (HCV group, 168.7 ± 41 ng/mL; fatty liver group, 106.7 ± 35 ng/mL), and between the chronic non-cirrhotic HCV group and the fatty liver group (I and IV) and the controls (35.1 ± 6 ng/mL). In the HCC group, the diagnostic value of OPN was comparable to that of AFP at a cutoff value of 280 ng/mL, achieving sensitivity, specificity, and overall accuracy of 100%, 98%, and 96%, respectively. Regarding the validity of plasma OPN as a predictor of fatty change, our results revealed a diagnostic accuracy of 50% with 70% sensitivity, 45% specificity, 50% positive predictive value, and 75% negative predictive value at a cutoff value of 134 ng/mL. CONCLUSIONS: Plasma OPN is comparable to AFP as a diagnostic marker and is related to the severity of liver involvement in HCC patients. Plasma OPN is of diagnostic potential value in NAFLD.
format Online
Article
Text
id pubmed-4612688
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Kowsar
record_format MEDLINE/PubMed
spelling pubmed-46126882015-10-23 Plasma Osteopontin Level in Chronic Liver Disease and Hepatocellular Carcinoma Fouad, Shawky Abdelhamid Mohamed, Nagwa Abdel Ghaffar Fawzy, Mary Wadie Moustafa, Doaa Ali Hepat Mon Research Article BACKGROUND: Osteopontin (OPN) is a secreted glycoprotein and is frequently associated with various tumors. OBJECTIVES: We sought to investigate the clinical usefulness of the level of plasma OPN, compared to α-fetoprotein (AFP), as a biomarker for hepatocellular carcinoma (HCC) and to evaluate its diagnostic value in nonalcoholic fatty liver disease (NAFLD) and its relationship with clinical and laboratory features of HCC and NAFLD. PATIENTS AND METHODS: The study was performed on 120 subjects classified into 5 groups: Group I included 25 chronic non-cirrhotic hepatitis C virus (HCV)-infected patients; Group II encompassed 25 patients with chronic HCV infection with liver cirrhosis; Group III comprised 25 patients with chronic HCV with liver cirrhosis and HCC; Group IV was comprised of 25 patients with NAFLD; and Group V consisted of 20 healthy age- and sex-matched controls. All the participants were subjected to history taking and clinical and abdominal ultrasonographic examinations as well as the following laboratory investigations: liver function tests, complete blood count, blood sugar, hepatitis B surface antigen, hepatitis C virus antibodies, HCV-RNA by qualitative polymerase chain reaction (for Groups I, II, and III) and serum AFP and plasma OPN levels. RESULTS: There were statistically significant differences in plasma OPN levels between the HCC group (401 ± 72 ng/mL) and the other groups, between the cirrhotic group (258.3 ± 35 ng/mL) and the non-cirrhotic group (HCV group, 168.7 ± 41 ng/mL; fatty liver group, 106.7 ± 35 ng/mL), and between the chronic non-cirrhotic HCV group and the fatty liver group (I and IV) and the controls (35.1 ± 6 ng/mL). In the HCC group, the diagnostic value of OPN was comparable to that of AFP at a cutoff value of 280 ng/mL, achieving sensitivity, specificity, and overall accuracy of 100%, 98%, and 96%, respectively. Regarding the validity of plasma OPN as a predictor of fatty change, our results revealed a diagnostic accuracy of 50% with 70% sensitivity, 45% specificity, 50% positive predictive value, and 75% negative predictive value at a cutoff value of 134 ng/mL. CONCLUSIONS: Plasma OPN is comparable to AFP as a diagnostic marker and is related to the severity of liver involvement in HCC patients. Plasma OPN is of diagnostic potential value in NAFLD. Kowsar 2015-09-01 /pmc/articles/PMC4612688/ /pubmed/26500684 http://dx.doi.org/10.5812/hepatmon.30753 Text en Copyright © 2015, Kowsar Corp http://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
spellingShingle Research Article
Fouad, Shawky Abdelhamid
Mohamed, Nagwa Abdel Ghaffar
Fawzy, Mary Wadie
Moustafa, Doaa Ali
Plasma Osteopontin Level in Chronic Liver Disease and Hepatocellular Carcinoma
title Plasma Osteopontin Level in Chronic Liver Disease and Hepatocellular Carcinoma
title_full Plasma Osteopontin Level in Chronic Liver Disease and Hepatocellular Carcinoma
title_fullStr Plasma Osteopontin Level in Chronic Liver Disease and Hepatocellular Carcinoma
title_full_unstemmed Plasma Osteopontin Level in Chronic Liver Disease and Hepatocellular Carcinoma
title_short Plasma Osteopontin Level in Chronic Liver Disease and Hepatocellular Carcinoma
title_sort plasma osteopontin level in chronic liver disease and hepatocellular carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612688/
https://www.ncbi.nlm.nih.gov/pubmed/26500684
http://dx.doi.org/10.5812/hepatmon.30753
work_keys_str_mv AT fouadshawkyabdelhamid plasmaosteopontinlevelinchronicliverdiseaseandhepatocellularcarcinoma
AT mohamednagwaabdelghaffar plasmaosteopontinlevelinchronicliverdiseaseandhepatocellularcarcinoma
AT fawzymarywadie plasmaosteopontinlevelinchronicliverdiseaseandhepatocellularcarcinoma
AT moustafadoaaali plasmaosteopontinlevelinchronicliverdiseaseandhepatocellularcarcinoma